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Abstract
Background
Most pregnancy hypertension estimates in less-developed countries are from cross-sec-
tional hospital surveys and are considered overestimates. We estimated population-based
rates by standardised methods in 27 intervention clusters of the Community-Level Interven-
tions for Pre-eclampsia (CLIP) cluster randomised trials.
Methods and findings
CLIP-eligible pregnant women identified in their homes or local primary health centres
(2013–2017). Included here are women who had delivered by trial end and received a visit
from a community health worker trained to provide supplementary hypertension-oriented
care, including standardised blood pressure (BP) measurement. Hypertension (BP� 140/
90 mm Hg) was defined as chronic (first detected at <20 weeks gestation) or gestational
(�20 weeks); pre-eclampsia was gestational hypertension plus proteinuria or a pre-eclamp-
sia-defining complication. A multi-level regression model compared hypertension rates and
types between countries (p < 0.05 considered significant). In 28,420 pregnancies studied,
women were usually young (median age 23–28 years), parous (53.7%–77.3%), with single-
tons (�97.5%), and enrolled at a median gestational age of 10.4 (India) to 25.9 weeks
(Mozambique). Basic education varied (22.8% in Pakistan to 57.9% in India). Pregnancy
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hypertension incidence was lower in Pakistan (9.3%) than India (10.3%), Mozambique
(10.9%), or Nigeria (10.2%) (p = 0.001). Most hypertension was diastolic only (46.4% in
India, 72.7% in Pakistan, 61.3% in Mozambique, and 63.3% in Nigeria). At first presentation
with elevated BP, gestational hypertension was most common diagnosis (particularly in
Mozambique [8.4%] versus India [6.9%], Pakistan [6.5%], and Nigeria [7.1%]; p < 0.001),
followed by pre-eclampsia (India [3.8%], Nigeria [3.0%], Pakistan [2.4%], and Mozambique
[2.3%]; p < 0.001) and chronic hypertension (especially in Mozambique [2.5%] and Nigeria
[2.8%], compared with India [1.2%] and Pakistan [1.5%]; p < 0.001). Inclusion of additional
diagnoses of hypertension and related complications, from household surveys or facility
record review (unavailable in Nigeria), revealed higher hypertension incidence: 14.0% in
India, 11.6% in Pakistan, and 16.8% in Mozambique; eclampsia was rare (<0.5%).
Conclusions
Pregnancy hypertension is common in less-developed settings. Most women in this study
presented with gestational hypertension amenable to surveillance and timed delivery to
improve outcomes.
Trial registration
This study is a secondary analysis of a clinical trial - ClinicalTrials.gov registration number
NCT01911494.
Author summary
Why was this study done?
• High blood pressure in pregnancy is thought to occur in up to 1 in 10 pregnant women.
• Most information is from more-developed countries or from referral hospitals in less-
developed countries, which is regarded to overestimate the occurrence of this condition.
What did the researchers do and find?
• As part of the Community-Level Interventions for Pre-eclampsia (CLIP) trials in 27
geographical clusters (India, Pakistan, Mozambique, and Nigeria; 2013–2017), we
undertook standardised blood pressure measurement in 28,420 pregnancies, in wom-
en’s homes or their primary health centres.
• Hypertension occurred in about 10% of pregnancies by standardised measurement,
usually based on elevation of only the bottom (diastolic) number and often diagnosed
for the first time postpartum; rates were 2%–7% higher when diagnoses from clinical
care were included.
• At first presentation with elevated blood pressure, most (7%–8%) hypertension was
pregnancy-induced (‘gestational’) without other associated problems.
Epidemiology of pregnancy hypertension
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What do these findings mean?
• In our study countries, hypertension in pregnancy was more common than previously
estimated.
• Most hypertension could only be measured with a blood pressure device, and not by
using a cuff and palpation alone.
• Most women presented with gestational hypertension that is amenable to surveillance
and timed delivery to decrease adverse outcomes for mothers and their offspring.
• Many women presented with hypertension only postpartum, highlighting the need for
ongoing surveillance of maternal well-being after birth.
Introduction
The United Nations Sustainable Development Goal (SDG) 3.1 aims to reduce the global mater-
nal mortality ratio to less than 70 per 100,000 live births by 2030 [1]. The SDGs aim to main-
tain the momentum of the Millennium Development Goals, which catalysed a global
reduction in maternal deaths from approximately 390,000 in 1990 to 275,000 in 2015 [1,2].
The burden of maternal mortality remains disproportionately borne by women in less-devel-
oped countries, particularly in sub-Saharan Africa (66%, 201,000 deaths) and southern Asia
(22%, 66,000 deaths) [3].
One of the leading causes of maternal death (and disability) worldwide is pregnancy hyper-
tension [4]. Incidence estimates from less-developed countries have varied from 4.0% to 12.3%
[4–9]. These estimates are based on facility-based cross-sectional cohort studies, which are
likely to overestimate rates compared with population-based data. Thus, the true incidence is
unknown. Adding further to these measurement challenges are a lack of access to quality ante-
natal care and blood pressure (BP) measurement, the lack of a standardised definition for pre-
eclampsia, and variable quality and coverage of routine health information systems; for exam-
ple, national demographic health surveys have reported that only half of women have a BP
measurement during antenatal care in Mozambique (54.4%) [10], and although the corre-
sponding figure in India is 89%, only half of women report receiving at least 4 antenatal care
visits [11].
Pregnancy hypertension is classified into 3 major categories: pre-existing (chronic) hyper-
tension, gestational hypertension, and pre-eclampsia (which includes eclampsia). In the World
Health Organization (WHO) Multicountry Survey on Maternal and Newborn Health—a
cross-sectional hospital-based survey of 313,030 women admitted to 357 health facilities in 29
countries across Africa, Asia, Latin America, and the Middle East—0.29% of women were
reported to have chronic hypertension (range 0.21% [Africa] to 0.32% [Western Pacific]) [12],
2.2% pre-eclampsia (excluding eclampsia; range 1.4% [Middle East] to 3.9% [Africa]), and
0.28% eclampsia (range 0.14% [Western Pacific] to 0.55% [Africa]) [12,13]; gestational hyper-
tension was excluded from the WHO multicountry survey estimates. Other published rates
have varied considerably; in hospital-based retrospective or prospective studies of variable size,
gestational hypertension has been reported to complicate 2%–3% of deliveries in Karachi,
Pakistan [14], 6.6% in south India [15], and 28.9% in southwest Nigeria [16,17].
Epidemiology of pregnancy hypertension
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We sought to establish reliable estimates of pregnancy hypertension incidence and type in 4
less-developed settings in southern Asia (India and Pakistan) and sub-Saharan Africa
(Mozambique and Nigeria), using BP data gathered in the community using a validated semi-
automated BP device from the Community-Level Interventions for Pre-eclampsia (CLIP) clus-
ter randomised controlled trials (NCT01911494) [18].
Methods
This is a secondary, planned analysis of data collected in the 4 countries and 27 intervention
clusters of the CLIP cluster randomised controlled trials (NCT01911494) [18], in India (N = 6,
Karnataka State), Pakistan (N = 10, Sindh Province), Mozambique (N = 6, Maputo and Gaza
Provinces), and Nigeria (N = 5, Ogun State). A STROBE checklist is provided (S2 Table).
In brief, pregnant women (aged 15–49 years in India, Pakistan, and Nigeria, and 12–49
years in Mozambique) were enrolled in the CLIP trials when they first declared their preg-
nancy and following informed consent. The CLIP intervention consisted of community
engagement and community health worker (CHW)–provided mobile health-guided clinical
assessment, initial treatment, and referral to facility. Surveillance data were collected by a sepa-
rate surveillance team, by quarterly household surveys in Pakistan, 6-monthly household sur-
veys in Mozambique and Nigeria, and a research registry of facility records in India. The
primary outcome was a composite of maternal, fetal, and newborn mortality and major mor-
bidity. The protocol has been published [18] and is included S1 Text, along with the statistical
analysis plan (S2 Text). The trials were approved by the University of British Columbia
Research Ethics Board (H12-03497) and within each country (MDC/IECHSR/2013-14/A,
India; 2590-Obs-ERC-13, Pakistan; 219/CNBS/13, Mozambique; OOUTH/DA.326/T/1/,
Nigeria).
The CLIP intervention was implemented in primarily rural areas of India (February 2014 to
October 2016), Pakistan (February 2014 to December 2016), Nigeria (March 2014 to January
2016), and Mozambique (February 2015 to February 2017). Within each country, a potential
cluster consisted of an established unit of the health system (i.e., primary health centre [PHC]
in India, union council in Pakistan, administrative post in Mozambique, and local government
area in Nigeria), consisting of all relevant villages and PHCs (other than in India, where the
PHC defined the cluster) within each unit. Potential clusters were chosen by the local team
(based on similar healthcare infrastructure, accessibility to the surveillance team, and the
absence of conflicting concurrent research activity). A random sample was then chosen, with
restricted, stratified central randomisation (according to population size and region) to the
intervention or to control (usual care).
In intervention clusters, CHWs were trained to provide mobile health-guided visits—sup-
plementary pregnancy hypertension-oriented antenatal and postpartum care at home (India,
Pakistan, and Mozambique) or at a PHC (Nigeria). Women in control clusters received usual
care, advocated by WHO as BP measurement (using the device available) and proteinuria test-
ing at each antenatal care visit at primary or other health centres; in these settings, most
women receive 1 such visit at PHCs, and few women receive 4. In none of the study countries
did CHWs usually either manage pregnancy hypertension or carry with them BP measure-
ment equipment or antihypertensive medication; further details of their training and usual
duties are detailed in S3 Text.
The CLIP intervention visits were guided by a novel mobile health application provided on
Android tablets—Pre-eclampsia Integrated Estimate of Risk on the Move (POM)—that pro-
vided step-by-step guidance for clinical assessment (including oximetry in Pakistan and
Mozambique), input of clinical data, and decision support for initial triage, transport, and
Epidemiology of pregnancy hypertension
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treatment of women identified with pregnancy hypertension or emergency medical conditions
[19]. This management was based on prediction of adverse maternal outcome and stillbirth,
derived from incorporation into POM of the miniPIERS predictive model in hypertensive
pregnancy [20]; this is a demographics-, symptom-, and sign-based model for use in low-
resource settings to identify the risk of adverse maternal outcome among women with preg-
nancy hypertension. Usability and feasibility testing supported experimental implementation
into clinical care [21].
POM-guided clinical assessment consisted of (i) a visual scan and enquiry for evidence of
an emergency condition that would warrant immediate referral (i.e., unconsciousness, stroke
or seizure, significant vaginal bleeding, or lack of fetal movement in the preceding 12 hours);
(ii) signs or symptoms suggestive of end-organ involvement of pre-eclampsia (i.e., maternal
symptoms of headache or visual disturbances, chest pain or dyspnoea, epigastric or right
upper quadrant abdominal pain, or vaginal bleeding with abdominal pain); (iii) BP measure-
ment; (iv) measurement of dipstick proteinuria both during the first antenatal visit and at all
visits at which the woman was hypertensive; and (v) blood oxygen saturation assessment,
using an Android mobile-phone- or tablet-adapted pulse oximeter to further improve risk
stratification (Mozambique and Pakistan only) [22]. Clinical assessments were recommended
every 4 weeks until 28 weeks gestation, every 2 weeks from 28 to 35 weeks, weekly from 36
weeks until delivery, once within 24 hours of birth, and postnatally around postpartum days 3,
7, and 14; in Nigeria, visits were opportunistic when women attended the PHC.
BP was measured using a semi-automated oscillometric device, validated for use in preg-
nancy and pre-eclampsia (Microlife 3AS1-2) [23]. CHWs were trained to have women rest for
5 minutes and then measure BP in a standardised fashion, at least twice (S3 Table). All BP
readings were manually entered into POM, which averaged them as the BP for that visit; the
first and second readings were averaged unless they were more than 10 mm Hg different, in
which case a third reading was requested and the second and third readings were averaged
[24]. The POM device provided guidance for community-initiated treatment (i.e., methyldopa
750 mg for systolic BP [sBP]� 160 mm Hg and intramuscular magnesium sulphate 10 g for
miniPIERS score > 25%) and referral (within 24 hours for sBP� 140 mm Hg, and within 4
hours for emergency conditions, sBP� 160 mm Hg, or miniPIERS score > 25%) [19].
Hypertension was defined as sBP� 140 mm Hg or diastolic BP (dBP)� 90 mm Hg. All
normotensive POM-guided visits were included until the woman was found to be hyperten-
sive, if applicable. Hypertension was defined as chronic (first detected at<20 weeks gestation)
or gestational (first detected at�20 weeks) [25]. The rates for pre-eclampsia (and eclampsia)
were estimated among pregnancies of women who were assessed and normotensive at<20
weeks gestation or who were first assessed at�20 weeks; pre-eclampsia was defined as gesta-
tional hypertension with proteinuria or 1 or more relevant end-organ complications [25].
Eclampsia was defined as seizure associated with pregnancy hypertension and was considered
as a form of pre-eclampsia (detailed definitions in S4 Table).
The data entered on the POM devices from women in intervention clusters were synchro-
nised and stored on Research Electronic Data Capture servers, and transferred regularly to the
University of British Columbia CLIP Co-ordinating Centre in Vancouver.
Trial surveillance data (i.e., baseline characteristics, processes of care and delivery, and
adverse maternal, perinatal, and neonatal outcomes) were based on maternal report and col-
lected by an independent team of fieldworkers trained in household surveillance (Pakistan,
Mozambique, and Nigeria) or were collected by review of facility records (India), initially on
paper and then electronically using tablets. Surveillance occurred quarterly in Pakistan,
6-monthly in Mozambique, and prospectively in near real time via the Global Network for
Women’s and Children’s Health Research’s Maternal Newborn Health Registry in India [26].
Epidemiology of pregnancy hypertension
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In Nigeria, trial surveillance data (which included extended baseline characteristics and out-
comes) were not available as surveillance was suspended and the trial closed shortly after the
pilot phase because of challenges identified in data entry from paper case report forms to the
electronic database; of note, POM device data in Nigeria (and all CLIP countries) were entered
directly into POM by the CHWs, a different team from those trained to conduct trial surveil-
lance. Data management protocols ensured data security by encryption, data tracking through
user identification numbers and audit trails, and effective data synchronisation between
devices within the same study cluster and with the Research Electronic Data Capture server.
For this analysis, we included pregnancies of women in intervention clusters who had received
at least 1 POM-guided visit and who had delivered by trial end. We excluded pregnancies of
women who were still on follow-up (i.e., undelivered) to avoid underestimation of hyperten-
sion incidence. Our focus was on the type of pregnancy hypertension at first presentation with
elevated BP in the community, to provide data for clinicians to inform individual counselling
and care; these data were derived from POM. Of additional interest was pregnancy hyperten-
sion incidence and type overall, to provide data for those responsible for planning resource
allocation; these data were derived from both POM and trial surveillance that included infor-
mation around the time of delivery.
The intervention clusters in each country were treated as 1 cohort for the purposes of our
primary analysis comparing pregnancy hypertension epidemiology (i.e., incidence, type, and
severity) between countries. In sensitivity analyses, hypertension incidence and type at presen-
tation were evaluated (i) among all pregnancies of women who received POM-guided visits,
regardless of delivery status (i.e., this analysis included women who were still undelivered at
the end of the trial), (ii) following adjustment for baseline maternal characteristics (i.e., age,
parity, and maternal basic education, except in Nigeria where data were not available), and
(iii) following incorporation of trial surveillance data that included data and diagnoses from
the household surveys and review of facility records. No adjustment was made for gestational
age at first POM-guided care visit or total number of visits because the relationship between
gestational age at a visit and probability of diagnosing hypertension is inconsistent, with a
nadir of BP at approximately 20 weeks, and the predominance of hypertension at term gesta-
tional age [24]. Continuous data were summarised by mean and standard deviation or median
and interquartile range, as appropriate, to avoid making assumptions about the distribution of
the data. Categorical data were summarised by number and proportion. Pairwise country
comparisons were made by chi-squared test and Wilcoxon signed rank test, as appropriate.
Between-country comparisons were made by chi-squared test for categorical variables and
Kruskal–Wallis test for continuous variables, as appropriate. Hypertension rates between
countries were compared using logistic regression, adjusting for country. Additional explana-
tory analyses were undertaken to explore the basis of any between-country differences based
on women’s baseline characteristics. Analyses were performed using R programming software
(version 3.3.2). p< 0.05 was considered statistically significant.
Results
Of the 44,794 pregnancies in CLIP intervention clusters, 12,211 (27.2%) did not receive at least
1 POM-guided visit, and 4,163 (9.3%) were not delivered by trial end, leaving 28,420 (63.4%)
pregnancies for inclusion in this analysis (Fig 1).
There were statistical differences between countries for all baseline pregnancy characteris-
tics (Table 1). At enrolment in CLIP, women in India and Mozambique were younger than
were those in Pakistan and Nigeria, but the absolute differences were very small. About one-
third of women were nulliparous, except in Pakistan, where the proportion was closer to one-
Epidemiology of pregnancy hypertension
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002783 April 12, 2019 6 / 16
Fig 1. Pregnancies enrolled and included in the study. POM, Pre-eclampsia Integrated Estimate of Risk on the Move.
https://doi.org/10.1371/journal.pmed.1002783.g001
Table 1. Patient characteristics for women who had received 1 or more POM-guided visits and were delivered by end of CLIP trial.
Characteristic India (N = 6,149) Pakistan (N = 10,904) Mozambique (N = 4,253) Nigeria (N = 7,114) p-Value�
Maternal age (years) 23 [20, 25] 28 [25, 30] 23 [19, 30] 27 [23, 31] <0.001
Missing 0 22 (0.2%) 146 (3.4%) 10 (0.1%)
Nulliparous 2,230 (36.3%) 2,481 (22.75%) 1,285 (30.2%) 2,180 (30.6%) <0.001
Maternal basic education† 3,560 (57.9%) 2,486 (22.8%) 2,486 (55.0%) Unknown‡ <0.001
Multiple pregnancies 53 (0.9%) 86 (0.8%) 105 (2.5%) Unknown‡ <0.001
GA at CLIP enrolment (weeks) 10.4 [7.9, 14.1] 18.7 [13.6, 24.6] 25.9 [19.5, 31.0] 16.6 [13.4, 18.4] <0.001
Pregnancies with antenatal visit(s) 6,120 (99.5%) 10,885 (99.8%) 4,234 (99.6%) 7,004 (98.5%) <0.001
GA at first POM-guided visit (weeks) 13.4 [9.5, 20.1] 21.9 [16.4, 28.4] 27.3 [22.4, 32.7] 28.0 [22.2, 33.4] <0.001
GA uncertain (antenatal or postpartum) at first POM-guided
visit
59 (0.96%) 50 (0.5%) 40 (0.9%) 164 (2.3%)
First POM-guided visit at <20 weeks 4,545 (73.7%) 4,430 (40.6%) 638 (15.0%) 1,147 (16.1%) <0.001
First POM-guided visit at�20 weeks 1,564 (25.4%) 6,425 (58.9%) 3,575 (84.1%) 5,827 (81.9%) <0.001
GA uncertain at first antenatal POM-guided visit 40 (0.6%) 49 (0.4%) 40 (0.9%) 140 (2.0%)
Pregnancies with postpartum visit(s) 3,759 (61.1%) 8,439 (77.4%) 3,434 (80.7%) 2,416 (34.0%) <0.001
GA at delivery (weeks) 39.3 [37.4, 40.4] 38.7 [36.3, 40.7] 39.3 [37.4, 41.0] 39.3 [37.4, 40.7]
Visits per pregnancy
Number of antenatal visits per pregnancy 8.0 [3.0, 12.0] 3 [2.0, 5.0] 4.0 [2.0, 6.0] 2.0 [1.0, 4.0] <0.001
Number postpartum visits per pregnancy 2.0 [1.0, 4.0] 2.0 [1.0, 3.0] 2.0 [1.0, 3.0] 3.0 [2.0, 4.0] <0.001
Data are number (%) of pregnancies or median [IQR].
�The p-value was based on comparisons of all groups by Kruskal-Wallis test for continuous variables, and chi-square test for categorical variables, as appropriate.
†Maternal basic education is defined as�8 years of schooling (India),�5 years of schooling (Pakistan), or achievement of Grade 5 or above (Mozambique).
‡Trial surveillance data was not available for Nigeria.
CLIP, Community-Level Interventions for Pre-eclampsia; GA, gestational age; POM, Pre-eclampsia Integrated Estimate of Risk on the Move.
https://doi.org/10.1371/journal.pmed.1002783.t001
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fifth. Women in India were enrolled earlier, usually at the end of the first trimester, compared
with enrolment predominantly in the second trimester in other countries, particularly in
Mozambique. Rates of maternal basic education were low overall, particularly in Pakistan.
There were more multiple pregnancies in Mozambique, but the proportion was still small
(<3%). CLIP data did not include information about smoking, body mass index, or prior pre-
eclampsia. In all countries, women who received 1 or more POM-guided visits and those who
did not were similar at baseline, although median gestational age at enrolment in CLIP was
2–4 weeks earlier for the former than for the latter (S5 Table); information was unavailable in
Nigeria (see Methods).
In�98.5% of informative pregnancies, there was an antenatal POM-guided visit, usually
within a few weeks of enrolment, other than in Nigeria, where there was a 3-month delay on
average (Table 1). As such, the first POM-guided visit occurred before 20 weeks gestation in
most (73.4%) pregnancies in India, just under half (40.6%) in Pakistan, and a distinct minority
(<20%) in Mozambique and Nigeria. In most pregnancies, there was a postpartum visit, other
than in Nigeria. Given the median gestational age at delivery, the median number of POM-
guided visits received by women was lower than the frequency recommended in the CLIP pro-
tocol, in India (i.e., 10 versus 14 recommended), Pakistan (i.e., 5 versus 11 recommended),
and Mozambique (i.e., 6 versus 10 recommended); data were not available in Nigeria. At the
majority of the 168,997 POM-guided visits in all countries, BP was measured, both antenatally
and postpartum (Table 2). As per the CLIP protocol, proteinuria was measured at>90% of the
first antenatal visits, and 91.2%–96.7% of subsequent antenatal visits at which the woman was
hypertensive, in all but Nigeria, where the proportion was lower (80.7%).
Approximately 10% of pregnancies in each of the 4 countries were identified as hyperten-
sive at a POM-guided visit (Table 3). The incidence was highest in Mozambique and lowest in
Pakistan. In most pregnancies, diagnostic criteria for hypertension were met based on isolated
dBP� 90 mm Hg, except in India, where the proportion was just under half. Few pregnancies
(<10% in all but Mozambique) were hypertensive based only on isolated systolic hypertension.
In few pregnancies overall was isolated diastolic hypertension later associated with systolic
hypertension (i.e., 75/295 [29.8%] in India, 58/734 [10.3%] in Pakistan, 20/285 [8.6%] in
Mozambique, and 34/457 [10.6%] in Nigeria, p< 0.001), other than in India, where women
presented earlier and had significantly more BP assessments. At least 85% of identified hyper-
tension was non-severe, least commonly in Nigeria.
In most pregnancies, hypertension was diagnosed antenatally (particularly in India), in the
mid-late third trimester (Table 3). However, in a substantial proportion of pregnancies
(approximately 40%), hypertension was first diagnosed by a POM-guided visit postpartum.
This occurred despite virtually all such women having been confirmed to be normotensive
antenatally, a median of under 2 weeks before delivery in all but Pakistan, where the last ante-
natal POM-guided visit was a median of 3 weeks before delivery. Postpartum hypertension
was usually diagnosed within 7 days of delivery, except in India; there, the incidence of post-
partum hypertension was lowest, and the timing of diagnosis was the most remote from deliv-
ery (i.e., median 10 days postpartum).
The incidence of chronic hypertension, reported only in pregnancies with an antenatal
POM-guided visit at<20 weeks gestation, was lower in India (1.2%) and Pakistan (1.5%) com-
pared with Mozambique (2.5%) and Nigeria (2.8%) (Table 3). When hypertension appeared at
�20 weeks gestation, gestational hypertension was most common, with a slightly higher rate
in Mozambique (8.4%) than in the other countries (approximately 7%). Most hypertension
was diagnosed antenatally in India and Mozambique, whereas about half was so diagnosed in
Pakistan and Nigeria.
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Pre-eclampsia incidence was similar in each of the 4 countries (2.3%–3.8% of women).
Most cases were diagnosed based on a broad definition that did not mandate the presence of
new proteinuria (see S3 Table for definitions). Approximately one-third of pregnancies with
pre-eclampsia demonstrated new proteinuria (other than in Mozambique, where the rate was
<10%), most women had relevant maternal symptoms, many had maternal signs (particularly
in Nigeria), and few (<5%) had reduced fetal movement. Rarely, women first presented with
eclampsia as their hypertensive disorder (1 case in India and 2 in Nigeria). Most pre-eclampsia
was diagnosed antenatally and near term, with about two-thirds presenting at�34 weeks ges-
tation; the exception was in India, where pre-eclampsia presented at a median of about 38
weeks. In the sensitivity analysis that adjusted for baseline maternal characteristics available,
rates of hypertension by type remained different between countries (S6 Table).
In sensitivity analyses, inclusion of women who were undelivered at the end of the trial
resulted in lower incidence estimates of hypertension in each country; this was true for any
hypertension and for each type (S6 Table). Adjustment for maternal characteristics (age, par-
ity, and education) revealed some differences of the 3 other countries from the comparator
India (S7 Table): In Pakistan, hypertension incidence overall remained lower than in India
(adjusted odds ratio [aOR] 0.75, 95% CI 0.67, 0.85; p< 0.001), and the observed lower rates of
gestational hypertension (aOR 0.84, 95% CI 0.73, 0.97; p = 0.016) and pre-eclampsia (aOR
0.50, 95% CI 0.41, 0.63; p< 0.001) reached statistical significance. In Mozambique, results
were similar to those from unadjusted analyses (not significant), except for a lower incidence
of pre-eclampsia than in India (aOR 0.51, 95% CI 0.40, 0.66; p< 0.001). In Nigeria, adjustment
for maternal age and parity (as education was unavailable) revealed a lower incidence of hyper-
tension overall than in India (aOR 0.82, 95% CI 0.73, 0.92; p< 0.001), associated with a higher
incidence of chronic hypertension (aOR 1.68, 95% CI 1.05, 2.70; p = 0.030) and a lower inci-
dence of pre-eclampsia (aOR 0.52, 95% CI 0.40, 0.67; p< 0.001). Finally, when we included
Table 2. Quality and nature of CLIP visits with POM mobile health application in intervention clusters in CLIP.
Characteristic India
(N = 6,149)
Pakistan
(N = 10,904)
Mozambique
(N = 4,253)
Nigeria
(N = 7,114)
p-Value�
Total number of visits performed 57,679 56,296 26,544 28,468 —
Antenatal 48,030 (83.3%) 38,386 (68.2%) 18,421 (69.4%) 21,510 (75.6%) —
Postpartum 9,647 (16.7%) 17,909 (31.8%) 8,122 (30.6%) 6,956 (24.4%) —
Timing uncertain 2 (0.0%) 1 (0.0%) 1 (0.0%) 2 (0.0%) —
Quality of visits
Number of visits at which BP measured 57,299 (99.3%) 56,234 (99.9%) 26,323 (99.2%) 28,264 (99.3%) <0.001
Antenatal 47,694 (99.3%) 38,339 (99.9%) 18,278 (99.2%) 21,313 (99.1%)
Postpartum 9,604 (99.6%) 17,895 (99.9%) 8,045 (99.1%) 6,950 (99.9%)
Timing uncertain 1 0 0 1
Proteinuria measured†
At first antenatal POM-guided visit (of those with an antenatal
visit)
5,676 (92.8%) 10,769 (98.9%) 4,143 (97.9%) 6,372 (91.0%) <0.001
At subsequent antenatal POM-guided visit at which the woman
was hypertensive
373 (91.2%) 235 (96.7%) 107 (94.7%) 175 (80.7%) <0.001
Data are number (%) of women.
�The p-value was based on comparisons of all groups by chi-squared test (only relevant for comparison of quality of visits).
†The CLIP protocol specified that proteinuria should be measured at the first CLIP visit, and then at subsequent visits at which the woman was hypertensive. In Nigeria,
proteinuria was measured at many subsequent visits regardless of BP status (12,796/21,354, 59.9%).
BP, blood pressure; CLIP, Community-Level Interventions for Pre-eclampsia; POM, Pre-eclampsia Integrated Estimate of Risk on the Move.
https://doi.org/10.1371/journal.pmed.1002783.t002
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hypertension and relevant end-organ complications documented by trial surveillance until 6
weeks postpartum (except in Nigeria, where these data were unavailable), estimates of preg-
nancy hypertension incidence rose, and were 36% higher in India (14.0% versus 10.3%), 25%
higher in Pakistan (11.6% versus 9.3%), and 54% higher in Mozambique (16.8% versus 10.9%)
(Table 4). Also, the relative proportions of types of hypertension differed because this approach
Table 3. Diagnosis of hypertension and its timing among pregnancies of women at a POM-guided visit.
India (N = 6,149) Pakistan (N = 10,904) Mozambique (N = 4,253) Nigeria (N = 7,114) p-Value�
Hypertension 636 (10.3%) 1,010 (9.3%) 465 (10.9%) 722 (10.2%) 0.009
Diagnostic criteria
Both sBP� 140 mm Hg and dBP� 90 mm Hg 295 (4.8%) 219 (2.0%) 94 (2.2%) 195 (2.7%) <0.001
Only sBP� 140 mm Hg 46 (0.7%) 57 (0.5%) 86 (2.0%) 70 (1.0%) <0.001
Only dBP� 90 mm Hg 295 (4.8%) 734 (6.7%) 285 (6.7%) 457 (6.4%) <0.001
Severity
Non-severe (sBP 140–159 or dBP 90–109 mm Hg) 593 (9.6%) 946 (8.7%) 430 (10.1%) 625 (8.8%) <0.001
Severe (sBP � 160 or dBP� 110 mm Hg) 43 (0.7%) 64 (0.6%) 35 (0.8%) 97 (1.4%) <0.001
Timing relative to delivery
Antenatal 512 (8.3%) 552 (5.1%) 290 (6.8%) 449 (6.3%) <0.001
GA at diagnosis (weeks) 36.0 [32.0, 39.0] 33.0 [26.0, 36.0] 35.0 [30.0, 38.0) 35.0 [27.0, 38.0) <0.001
GA uncertain 7/512 (1.4%) 3/552 (0.5%) 3/290 (1.0%) 15/449 (3.3%)
Postpartum 124 (2.0%) 458 (4.2%) 175 (4.1%) 272 (3.8%) <0.001
Timing (days postpartum) 10.0 [6.0, 15.0] 6.0 [3.0, 11.0] 7.0 [4.0, 13.0] 3.0 [1.0, 7.0] <0.001
Timing uncertain 1 (0.02%) 0 0 0
Had an antenatal POM-guided visit 124/124 (100.0%) 457/458 (99.8%) 173/175 (98.9%) 253/272 (93.0%)
Timing of last POM-guided visit before delivery (days) 5.0 [3.0, 8.0] 22.0 [13.0, 31.0] 7.0 [4.0, 14.0] 12.0 [5.0, 25.0]
Timing uncertain 0 0 0 1 (0.01%)
Hypertension type at first diagnosis
Chronic hypertension† 54/4,545 (1.2%) 65/4,430 (1.5%) 16/638 (2.5%) 32/1,147 (2.8%) <0.001
Gestational hypertension† 372/5,416 (6.9%) 690/10,543 (6.5%) 349/4,156 (8.4%) 475/6,676 (7.1%)
Diagnosed antenatally 273/5,416 (5.0%) 313/10,543 (3.0%) 203/4,156 (4.9%) 226/6,676 (3.4%)
Diagnosed postpartum 99/5,416 (1.8%) 377/10,543 (3.6%) 146/4,156 (3.5%) 249/6,676 (3.7%)
Pre-eclampsia† (including eclampsia) 204/5,416 (3.8%) 251/10,543 (2.4%) 96/4,156 (2.3%) 199/6,676 (3.0%)
Pre-eclampsia diagnostic criteria met‡
Proteinuria 59/5,416 (1.1%) 88/10,543 (0.8%) 8/4,156 (0.2%) 72/6,676 (1.1%)
Maternal symptoms 152/5,416 (2.8%) 224/10,543 (2.1%) 72/4,156 (1.7%) 146/6,676 (2.2%)
Maternal signs (including eclampsia) 42/5,416 (0.8%) 62/10,543 (0.6%) 30/4,156 (0.7%) 87/6,676 (1.3%)
No fetal movement 4/5,416 (0.1%) 6/10,543 (0.1%) 3/4,156 (0.1%) 1/6,676 (0.01%)
GA at pre-eclampsia onset (weeks) 37.9 [35.5, 39.4] 35.6 [31.3, 38.2] 36.9 [31.5, 39.8] 36.0 [32.0, 39.3] <0.001
GA < 34 weeks 36/204 (17.7%) 99/251 (39.4%) 33/96 (34.4%) 70/199 (35.9%) <0.001
GA� 34 weeks 168/204 (82.4%) 152/251 (60.6%) 63/96 (65.6%) 129/199 (64.8%) <0.001
Hypertension type not knownǁ 6 (0.1%) 4 (0.04%) 4 (0.1%) 16 (0.2%) 0.004
Data are number (%) of women or median [IQR].
�The p-value was based on comparisons of all groups by Kruskal–Wallis test for continuous variables, and chi-squared test for categorical variables, as appropriate.
†Chronic hypertension incidence was estimated only among women who were assessed at <20 weeks gestation. Gestational hypertension and pre-eclampsia incidence
were estimated among women who were previously assessed as normotensive at <20 weeks or assessed for the first time at�20 weeks. For complete definitions please
see S3 Table.
‡Not mutually exclusive.
kUnknown because GA at hypertension diagnosis not known.
dBP, diastolic blood pressure; GA, gestational age; sBP, systolic blood pressure; POM, Pre-eclampsia Integrated Estimate of Risk on the Move.
https://doi.org/10.1371/journal.pmed.1002783.t003
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also accounted for progression to pre-eclampsia/eclampsia at either subsequent POM-guided
visits or according to trial surveillance. Overall, chronic hypertension was rare (<1.0% of preg-
nancies in all countries), gestational hypertension most common (6%–12% of pregnancies,
highest in Mozambique), and pre-eclampsia intermediate in incidence (3%–6%, highest in
India).
Discussion
In almost 30,000 pregnancies from 27 CLIP intervention clusters in sub-Saharan Africa and
southern Asia, use of standardised BP measurement revealed an incidence of pregnancy
hypertension of approximately 10%. The rate was slightly lower in Pakistan, but the difference
was not explained by between-country differences in measurable baseline maternal and preg-
nancy characteristics.
Our community-based incidence estimates of pregnancy hypertension types revealed that
chronic hypertension was least common (approximately 1%–3% of pregnancies), gestational
hypertension most common (approximately 6%–8%), and pre-eclampsia intermediate in inci-
dence (2%–4%); eclampsia was rare (<1%) and was included within estimates of pre-eclamp-
sia. Most pre-eclampsia diagnoses were based on a broad definition rather than proteinuria
alone (present in up to 33% of pre-eclampsia pregnancies).
Most of the hypertension detected was solely diastolic, particularly when non-severe; this
means that ascertainment of BP by palpation, which detects only systolic hypertension, would
be both inadequate and inaccurate for clinical care in these settings. Most hypertension was
diagnosed antenatally, usually in the mid-third trimester, supporting WHO recommendations
for increased frequency of antenatal care visits and BP measurement approaching term gesta-
tion [27]. Importantly, a substantial number of women were first diagnosed with hypertension
postpartum (despite being normotensive at antenatal CHW visits), emphasising the impor-
tance of post-delivery BP measurements in clinical care beyond the WHO recommendation to
measure BP within the 24 hours after delivery [28].
The major strengths of our study are the population-based nature of recruitment, and stan-
dardised BP measurements, using a pregnancy-validated BP device [23]. We had a large sam-
ple size and evaluated women in 4 less-developed sub-Saharan and southern Asian countries.
We estimated rates of chronic hypertension only among women who presented at<20 weeks
gestation, an important consideration because most women in all but India first present for
Table 4. Diagnosis of hypertension based on POM-guided community care and trial surveillance�.
Hypertension type India (N = 6,149) Pakistan (N = 10,904) Mozambique (N = 4,253) Nigeria (N = 7,114) p-Value†
Chronic hypertension (without pre-eclampsia) 39 (0.6%) 40 (0.4%) 14 (0.3%) 30 (0.4%) 0.047
Gestational hypertension (without pre-eclampsia) 464 (7.5%) 753 (6.9%) 497 (11.7%) 441 (6.2%) <0.001
Pre-eclampsia (including eclampsia) 353 (5.7%) 468 (4.3%) 198 (4.7%) 235 (3.3%) <0.001
From chronic hypertension 15/54 (27.8%) 25/65 (38.5%) 2/16 (12.5%) 2/32 (6.3%)
From gestational hypertension 74/372 (19.9%) 129/690 (18.7%) 56/349 (16.1%) 34/475 (7.2%)
Eclampsia 17 (0.3%) 13 (0.1%) 15 (0.4%) 3 (0.0%) <0.001
Hypertension type uncertain 7 (0.1%) 4 (0.04%) 4 (0.1%) 16 (0.2%)
Overall estimate of pregnancy hypertension 863 (14.0%) 1,265 (11.6%) 713 (16.8%) 722 (10.2%) <0.001
Data are number (%) of pregnancies.
�Trial surveillance data were not available for Nigeria.
†The p-value was based on comparisons of all groups by chi-squared test for categorical variables.
POM, Pre-eclampsia Integrated Estimate of Risk on the Move.
https://doi.org/10.1371/journal.pmed.1002783.t004
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antenatal care beyond the first half of pregnancy, when chronic hypertension can be diag-
nosed. We evaluated women using repeated community BP measurements in the days after
birth (which are often not performed even in well-resourced settings).
Limitations of this analysis include the fact that we had BP measurements by standardised
methods only from community care, as facility care was not the focus of the CLIP trial. Our
trial surveillance included documentation of hypertension and related complications from
facility records and from women themselves; these data were included in a sensitivity analysis
that suggested that our community estimates are conservative, possibly related to substantial
numbers of women presenting with hypertension at the end of their pregnancy or around
labour and delivery, at which point care did not include CHW-led community visits. CHWs
were unable to perform their community assessments as frequently as specified in the CLIP
protocol, particularly the weekly visits from 36 weeks until delivery; as such, we may have
missed the onset of hypertension just before delivery, as suggested by the higher incidence of
hypertension when we incorporated non-standardised clinical assessments of BP from trial
surveillance. We were unable to adjust for gestational age at the initiation of POM-guided vis-
its or for the number of visits, given the lack of a consistent relationship between gestational
age at a visit and the probability of diagnosing hypertension; however, we will explore the rela-
tionship between the number of POM-guided visits and outcomes in future planned ‘dose–
response’ analyses (S2 Text). We applied internationally agreed-upon definitions of pregnancy
hypertension type based on gestational age at presentation [25]; we recognise that a limitation
of this approach is that women who were assessed for the first time at�20 weeks gestation and
found to be hypertensive could have been labelled as having gestational hypertension when in
fact they had chronic hypertension, with/without a secondary cause such as renal disease.
However, our approach is recognised to be the relevant clinical approach given the propensity
of pre-eclampsia to progress, which must, as much as possible, be under observation. We were
unable to include all end-organ complications of pre-eclampsia, assessed clinically or through
laboratory tests; however, trial surveillance did incorporate those complications that would
have been diagnosed and treated at facility. We had only basic maternal characteristics avail-
able for use in our adjusted analysis of hypertension rates and types by country. No informa-
tion was available on past history of chronic hypertension, so our rates for chronic
hypertension may be underestimated, particularly as many women first presented for antena-
tal care in the second half of pregnancy and so chronic hypertension could not be assessed
directly. Of course, an estimate from any region cannot be assumed to be automatically gener-
alisable to the whole country.
To our knowledge, this is the first study of pregnancy hypertension incidence and type in
less-developed countries that is both population-based in terms of participants and standard-
ised in terms of BP measurement, by positioning and use of a pregnancy-validated BP device
[23]. Prior estimates from less-developed countries have varied from 4.0% to 12.3% and come
primarily from facility-based cross-sectional cohort studies [4–9]. While such studies have
been thought to overestimate pregnancy hypertension incidence, our data suggest that this
may not be true. Our estimates are at least as high as those from more-developed settings [4]
and still probably conservative given the impact of the addition of non-standardised clinical
BP assessments made around the time of delivery and documented by trial surveillance.
Our estimate of chronic hypertension incidence resembles the 1%–2% from more-devel-
oped settings [4]. Our data are unique from less-developed settings as many women were eval-
uated at<20 weeks gestation.
As in well-resourced settings, gestational hypertension was the most common type of preg-
nancy hypertension in our study population (approximately 6%–8%). The rates we found are
as high or higher than those published from facility-based retrospective or prospective cohort
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studies: 6.9% in India (compared with 6.6% published [15]), 6.5% in Pakistan (versus 1.7%
published [14]), and 7.1% in Nigeria (compared with highly variable estimates from 1.3% [17]
to 28.9% [16]); we identified no comparable published data in Mozambique. Of note, the
median gestational age at enrolment in Mozambique and Nigeria was over 20 weeks; although
it is possible that some cases of gestational hypertension were actually cases of chronic hyper-
tension, the incidence of gestational hypertension in Mozambique and Nigeria was similar to
that in India, where the median gestational age of enrolment was 13 weeks.
The incidence of pre-eclampsia in our study was similar to published rates of 2%–4% in
more-developed countries [4], but slightly higher than rates previously documented in our
study countries: 3.8% in India (versus 2.0% published [12]), 2.4% in Pakistan (versus 1.2%
published [12]), and 3.0% in Nigeria (versus 2.3%–4.2% [12,17,29]); there were no comparable
published data in Mozambique. Few women presented with eclampsia during community-
based visits. The incidence of pre-eclampsia was lower than that of gestational hypertension,
despite the broad definition of pre-eclampsia used in the study (i.e., without mandatory
proteinuria).
A novel finding of this study is the high proportion of women diagnosed with hypertension
based on dBP alone, and the fact that most did not go on to develop systolic hypertension at
subsequent POM-guided visits. While the pregnancy hypertension literature to date has
focused on dBP as a diagnostic criterion [30], this practice has been based on the greater sus-
ceptibility of sBP to environmental influences, rather than a regard for dBP being more impor-
tant. However, outside pregnancy, high isolated dBP is characteristic of hypertension in the
young [31] (as in our population), among whom it is the measure associated with elevated car-
diovascular risk; it is in older populations that this association is assumed by systolic hyperten-
sion [31].
Finally, we have documented high rates of new postpartum hypertension (approximately
20%–45% of all cases of hypertension) based on a median of 2 postpartum CHW-led commu-
nity visits and normal BP at antenatal visits. Comparable rates in either less- or more-devel-
oped countries are unknown, but in the latter, a rate of 2% has been estimated during the
period prior to hospital discharge [32,33].
CHWs can measure BP and respond to hypertension; this has implications beyond mater-
nity care to the broader SDG agenda related to non-communicable diseases [1]. Pregnancy
hypertension is at least as common in less-developed countries as it is in more-developed.
During active community surveillance of antenatal BP, most women present with non-severe
elevations of BP due to gestational hypertension. As such, the severity and type of hypertension
are amendable to intervention, by antihypertensive therapy [34] or timed delivery to optimise
outcomes, particularly where there is limited capacity for the healthcare infrastructure to
respond to obstetric emergencies. Future research should address, in particular, postnatal BP
measurement and management.
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